(DSY) Dassault Systemes SE - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0014003TT8
Stock: 3D Modeling, Simulation, Collaboration, Platform
Total Rating 26
Risk 85
Buy Signal -0.65
| Risk 5d forecast | |
|---|---|
| Volatility | 27.6% |
| Relative Tail Risk | -5.91% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.03 |
| Alpha | -61.05 |
| Character TTM | |
|---|---|
| Beta | 0.195 |
| Beta Downside | 0.320 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.60% |
| CAGR/Max DD | -0.32 |
EPS (Earnings per Share)
Revenue
Description: DSY Dassault Systemes SE February 28, 2026
Dassault Systèmes SE (ticker DSY) develops and sells a broad portfolio of 3-D modeling, simulation, and collaborative software-including SOLIDWORKS, CATIA, ENOVIA, SIMULIA, DELMIA and the 3DEXPERIENCE platform-targeting industries such as aerospace, automotive, life sciences, and construction. Its solutions are delivered through a mix of direct sales, indirect channels, and global partners.
In FY 2023 the company generated €5.44 billion in revenue, up 4 % year-over-year, with an operating margin of 22 %. Subscription and cloud-based services now represent roughly 55 % of total revenue, and annual recurring revenue (ARR) grew about 30 % YoY, reflecting accelerating demand for digital-twin and AI-enabled design tools.
Key macro drivers include rising EU and U.S. spending on Industry 4.0 initiatives, the shift toward virtual product development accelerated by supply-chain constraints, and growing regulatory pressure in life-sciences that favors integrated simulation platforms. These trends underpin Dassault Systèmes’ positioning in high-growth segments such as autonomous vehicle design and pharmaceutical R&D.
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed valuation models.
Headlines to watch out for
- Subscription revenue growth drives software segment expansion
- Industrial sector demand impacts 3D modeling software sales
- Cloud platform adoption boosts recurring revenue streams
- Life sciences software solutions expand market penetration
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 1.20b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.32 > 1.0 |
| NWC/Revenue: 40.99% < 20% (prev 49.02%; Δ -8.03% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.63b > Net Income 1.20b |
| Net Debt (-1.53b) to EBITDA (2.03b): -0.75 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.33b) vs 12m ago -0.12% < -2% |
| Gross Margin: 82.39% > 18% (prev 0.82%; Δ 8.16k% > 0.5%) |
| Asset Turnover: 40.75% > 50% (prev 39.97%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: 46.15 > 6 (EBITDA TTM 2.03b / Interest Expense TTM 32.3m) |
Altman Z''
| A: 0.17 (Total Current Assets 6.79b - Total Current Liabilities 4.23b) / Total Assets 15.06b |
| B: error (Retained Earnings missing) |
| C: 0.10 (EBIT TTM 1.49b / Avg Total Assets 15.30b) |
| D: 1.40 (Book Value of Equity 8.79b / Total Liabilities 6.26b) |
Beneish M -3.07
| DSRI: 1.02 (Receivables 2.21b/2.15b, Revenue 6.24b/6.21b) |
| GMI: 1.00 (GM 82.39% / 82.16%) |
| AQI: 0.94 (AQ_t 0.49 / AQ_t-1 0.52) |
| SGI: 1.00 (Revenue 6.24b / 6.21b) |
| TATA: -0.03 (NI 1.20b - CFO 1.63b) / TA 15.06b) |
| Beneish M-Score: -3.07 (Cap -4..+1) = AA |
What is the price of DSY shares?
As of March 14, 2026, the stock is trading at EUR 18.04 with a total of 3,047,686 shares traded.
Over the past week, the price has changed by -1.28%, over one month by +3.79%, over three months by -21.63% and over the past year by -51.52%.
Over the past week, the price has changed by -1.28%, over one month by +3.79%, over three months by -21.63% and over the past year by -51.52%.
Is DSY a buy, sell or hold?
Dassault Systemes SE has no consensus analysts rating.
What are the forecasts/targets for the DSY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 23.7 | 31.4% |
| Analysts Target Price | - | - |
DSY Fundamental Data Overview March 12, 2026
Market Cap USD = 27.42b (23.73b EUR * 1.1554 EUR.USD)
P/E Trailing = 20.0278
P/E Forward = 13.5501
P/S = 3.8053
P/B = 2.702
P/EG = 5.2132
Revenue TTM = 6.24b EUR
EBIT TTM = 1.49b EUR
EBITDA TTM = 2.03b EUR
Long Term Debt = 1.15b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.45b EUR (from shortTermDebt, last quarter)
Debt = 2.60b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.53b EUR (from netDebt column, last quarter)
Enterprise Value = 22.20b EUR (23.73b + Debt 2.60b - CCE 4.13b)
Interest Coverage Ratio = 46.15 (Ebit TTM 1.49b / Interest Expense TTM 32.3m)
EV/FCF = 15.11x (Enterprise Value 22.20b / FCF TTM 1.47b)
FCF Yield = 6.62% (FCF TTM 1.47b / Enterprise Value 22.20b)
FCF Margin = 23.56% (FCF TTM 1.47b / Revenue TTM 6.24b)
Net Margin = 19.18% (Net Income TTM 1.20b / Revenue TTM 6.24b)
Gross Margin = 82.39% ((Revenue TTM 6.24b - Cost of Revenue TTM 1.10b) / Revenue TTM)
Gross Margin QoQ = 84.97% (prev 78.05%)
Tobins Q-Ratio = 1.47 (Enterprise Value 22.20b / Total Assets 15.06b)
Interest Expense / Debt = 0.17% (Interest Expense 4.40m / Debt 2.60b)
Taxrate = 16.80% (88.2m / 525.1m)
NOPAT = 1.24b (EBIT 1.49b * (1 - 16.80%))
Current Ratio = 1.60 (Total Current Assets 6.79b / Total Current Liabilities 4.23b)
Debt / Equity = 0.30 (Debt 2.60b / totalStockholderEquity, last quarter 8.79b)
Debt / EBITDA = -0.75 (Net Debt -1.53b / EBITDA 2.03b)
Debt / FCF = -1.04 (Net Debt -1.53b / FCF TTM 1.47b)
Total Stockholder Equity = 8.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 1.20b / Total Assets 15.06b)
RoE = 13.97% (Net Income TTM 1.20b / Total Stockholder Equity 8.56b)
RoCE = 15.36% (EBIT 1.49b / Capital Employed (Equity 8.56b + L.T.Debt 1.15b))
RoIC = 11.16% (NOPAT 1.24b / Invested Capital 11.11b)
WACC = 5.99% (E(23.73b)/V(26.32b) * Re(6.63%) + D(2.60b)/V(26.32b) * Rd(0.17%) * (1-Tc(0.17)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.31%
[DCF] Terminal Value 86.14% ; FCFF base≈1.47b ; Y1≈1.49b ; Y5≈1.64b
[DCF] Fair Price = 37.28 (EV 47.42b - Net Debt -1.53b = Equity 48.95b / Shares 1.31b; r=5.99% [WACC]; 5y FCF grow 1.61% → 2.90% )
EPS Correlation: 56.35 | EPS CAGR: 11.05% | SUE: -3.12 | # QB: 0
Revenue Correlation: 62.77 | Revenue CAGR: 6.56% | SUE: -3.36 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.30 | Chg7d=+0.000 | Chg30d=-0.011 | Revisions Net=-3 | Analysts=8
EPS current Year (2026-12-31): EPS=1.33 | Chg7d=-0.001 | Chg30d=-0.047 | Revisions Net=-8 | Growth EPS=+1.2% | Growth Revenue=+1.9%
EPS next Year (2027-12-31): EPS=1.42 | Chg7d=-0.003 | Chg30d=-0.081 | Revisions Net=-14 | Growth EPS=+6.9% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = -2.0% (Analyst 1.0% - Implied 3.0%)
P/E Trailing = 20.0278
P/E Forward = 13.5501
P/S = 3.8053
P/B = 2.702
P/EG = 5.2132
Revenue TTM = 6.24b EUR
EBIT TTM = 1.49b EUR
EBITDA TTM = 2.03b EUR
Long Term Debt = 1.15b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.45b EUR (from shortTermDebt, last quarter)
Debt = 2.60b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.53b EUR (from netDebt column, last quarter)
Enterprise Value = 22.20b EUR (23.73b + Debt 2.60b - CCE 4.13b)
Interest Coverage Ratio = 46.15 (Ebit TTM 1.49b / Interest Expense TTM 32.3m)
EV/FCF = 15.11x (Enterprise Value 22.20b / FCF TTM 1.47b)
FCF Yield = 6.62% (FCF TTM 1.47b / Enterprise Value 22.20b)
FCF Margin = 23.56% (FCF TTM 1.47b / Revenue TTM 6.24b)
Net Margin = 19.18% (Net Income TTM 1.20b / Revenue TTM 6.24b)
Gross Margin = 82.39% ((Revenue TTM 6.24b - Cost of Revenue TTM 1.10b) / Revenue TTM)
Gross Margin QoQ = 84.97% (prev 78.05%)
Tobins Q-Ratio = 1.47 (Enterprise Value 22.20b / Total Assets 15.06b)
Interest Expense / Debt = 0.17% (Interest Expense 4.40m / Debt 2.60b)
Taxrate = 16.80% (88.2m / 525.1m)
NOPAT = 1.24b (EBIT 1.49b * (1 - 16.80%))
Current Ratio = 1.60 (Total Current Assets 6.79b / Total Current Liabilities 4.23b)
Debt / Equity = 0.30 (Debt 2.60b / totalStockholderEquity, last quarter 8.79b)
Debt / EBITDA = -0.75 (Net Debt -1.53b / EBITDA 2.03b)
Debt / FCF = -1.04 (Net Debt -1.53b / FCF TTM 1.47b)
Total Stockholder Equity = 8.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.81% (Net Income 1.20b / Total Assets 15.06b)
RoE = 13.97% (Net Income TTM 1.20b / Total Stockholder Equity 8.56b)
RoCE = 15.36% (EBIT 1.49b / Capital Employed (Equity 8.56b + L.T.Debt 1.15b))
RoIC = 11.16% (NOPAT 1.24b / Invested Capital 11.11b)
WACC = 5.99% (E(23.73b)/V(26.32b) * Re(6.63%) + D(2.60b)/V(26.32b) * Rd(0.17%) * (1-Tc(0.17)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.31%
[DCF] Terminal Value 86.14% ; FCFF base≈1.47b ; Y1≈1.49b ; Y5≈1.64b
[DCF] Fair Price = 37.28 (EV 47.42b - Net Debt -1.53b = Equity 48.95b / Shares 1.31b; r=5.99% [WACC]; 5y FCF grow 1.61% → 2.90% )
EPS Correlation: 56.35 | EPS CAGR: 11.05% | SUE: -3.12 | # QB: 0
Revenue Correlation: 62.77 | Revenue CAGR: 6.56% | SUE: -3.36 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.30 | Chg7d=+0.000 | Chg30d=-0.011 | Revisions Net=-3 | Analysts=8
EPS current Year (2026-12-31): EPS=1.33 | Chg7d=-0.001 | Chg30d=-0.047 | Revisions Net=-8 | Growth EPS=+1.2% | Growth Revenue=+1.9%
EPS next Year (2027-12-31): EPS=1.42 | Chg7d=-0.003 | Chg30d=-0.081 | Revisions Net=-14 | Growth EPS=+6.9% | Growth Revenue=+5.5%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.0% (Discount Rate 7.9% - Earnings Yield 5.0%)
[Growth] Growth Spread = -2.0% (Analyst 1.0% - Implied 3.0%)